Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

The final appraisal document for Dupixent (dupilumab) has given the green ... It is the second indication for the IL-4 and IL-13 inhibitor cleared for use by the NHS in England and Wales after ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ADBRY®/ADTRALZA® (tralokinumab) to market. Its less frequent dosing, more selective IL-13 ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

We feel IL-13 and IL-4, addressing both those cytokines ... is pretty interesting from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out exactly why former ...

IL-4/IL-13 stimulated release of TGFβ1, in synergy with eotaxin-3, promote fibroblast activation and differentiation into myofibroblast, ultimately leading to ECM deposition and smooth muscle cells ...

are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120). Thus, the possible protective role of basophil-derived IL-4/IL-13 in MI should ...

EBGLYSS™ (lebrikizumab) developed by Eli Lilly and Co and Almirall | Atopic dermatitis EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab ...